Actions
Incoming Resources
- Medicare, Medicaid, and other health provisions in the American Taxpayer Relief Act of 2012, Amanda K. Sarata [and eleven others]
- Prescription drug importation, Amanda K. Sarata, Agata Dabrowska
- Funding for ACA-Established Patient-Centered Outcomes Research Trust Fund (PCORTF) extended through FY2029, Amanda K. Sarata
- Genetic testing, background and policy issues, Amanda K. Sarata
- The agency for healthcare research and quality (AHRQ) budget, fact sheet, Amanda K. Sarata
- Genomic data and privacy, background and relevant law, Amanda K. Sarata [and three others]
- FDA Reauthorization Act of 2017 (FDARA, P.L. 115-52), Amanda K. Sarata [and three others]
- Health care-related expiring provisions of the 116th Congress, First Session, Amanda K. Sarata [and ten others]
- Private health information and prescription drug monitoring programs, Amanda K. Sarata
- Mental health parity and mandated coverage of mental health and substance use disorder services after the ACA, Amanda K. Sarata
- HHS announcement on FDA premarket review of laboratory-developed tests (LDTs), Amanda K. Sarata
- Measuring health care quality, measure development, endorsement, and implementation, Amanda K. Sarata
- Accountable care organizations and the Medicare Shared Savings Program, Amanda K. Sarata
- Employer wellness programs, health reform and the Genetic Information Nondiscrimination Act, Amanda K. Sarata
- Updated Common Rule, key changes for research using stored biospecimens, Amanda K. Sarata
- Privacy protections for individuals with substance use disorders, the part 2 final rule in brief, Amanda K. Sarata, C. Stephen Redhead
- The Genetic Information Nondiscrimination Act of 2008 (GINA), Amanda K. Sarata, Jody Feder
- Public health, workforce, quality, and other provisions in H.R. 3962, Amanda K. Sarata [and thirteen others]
- COVID-19 testing, key issues, Amanda K. Sarata
- Genetic discrimination, overview of the issue and proposed legislation, Amanda K. Sarata, Erin D. Williams
- The Genetic Information Nondiscrimination Act of 2008 and the Patient Protection and Affordable Care Act of 2010, overview and legal analysis of potential interactions
- Health care quality, enhancing provider accountability through payment incentives and public reporting, Amanda K. Sarata
- Regulation of clinical tests, in vitro diagnostic (IVD) devices, laboratory developed tests (LDTs), and genetic tests, Amanda K. Sarata, Judith A. Johnson
- Early development and regulation of diagnostic testing for COVID-19, frequently asked questions, Amanda K. Sarata
- Financing and delivery of behavioral health services and the Patient Protection and Affordable Care Act, Amanda K. Sarata, Erin Bagalman
- Clinical fentanyl testing, Amanda K. Sarata
- COVID-19 variants, vaccines, diagnostics, and therapeutics, Amanda K. Sarata, Agata Bodie, Kavya Sekar
- Mental health parity and the Patient Protection and Affordable Care Act of 2010, Amanda K. Sarata
- Employer wellness programs and genetic information, frequently asked questions, Amanda K. Sarata
- FDA regulation of laboratory-developed tests (LDTs), Amanda K. Sarata
- Prescription drug importation, Amanda K. Sarata, Agata Dabrowska
- Medicare, Medicaid, and other health provisions in the American Taxpayer Relief Act of 2012, Amanda K. Sarata [and eleven others]
- Updated Common Rule, key changes for research using stored biospecimens, Amanda K. Sarata
- Privacy protections for individuals with substance use disorders, the part 2 final rule in brief, Amanda K. Sarata, C. Stephen Redhead
- Funding for ACA-Established Patient-Centered Outcomes Research Trust Fund (PCORTF) extended through FY2029, Amanda K. Sarata
- Genetic testing, background and policy issues, Amanda K. Sarata
- The Genetic Information Nondiscrimination Act of 2008 (GINA), Amanda K. Sarata, Jody Feder
- Genomic data and privacy, background and relevant law, Amanda K. Sarata [and three others]
- FDA Reauthorization Act of 2017 (FDARA, P.L. 115-52), Amanda K. Sarata [and three others]
- Health care-related expiring provisions of the 116th Congress, First Session, Amanda K. Sarata [and ten others]
- Measuring health care quality, measure development, endorsement, and implementation, Amanda K. Sarata
- HHS announcement on FDA premarket review of laboratory-developed tests (LDTs), Amanda K. Sarata
- Mental health parity and mandated coverage of mental health and substance use disorder services after the ACA, Amanda K. Sarata
- Private health information and prescription drug monitoring programs, Amanda K. Sarata
- Employer wellness programs, health reform and the Genetic Information Nondiscrimination Act, Amanda K. Sarata
- The agency for healthcare research and quality (AHRQ) budget, fact sheet, Amanda K. Sarata
- Genetic discrimination, overview of the issue and proposed legislation, Amanda K. Sarata, Erin D. Williams
- COVID-19 testing, key issues, Amanda K. Sarata
- The Genetic Information Nondiscrimination Act of 2008 and the Patient Protection and Affordable Care Act of 2010, overview and legal analysis of potential interactions
- Public health, workforce, quality, and other provisions in H.R. 3962, Amanda K. Sarata [and thirteen others]
- Regulation of clinical tests, in vitro diagnostic (IVD) devices, laboratory developed tests (LDTs), and genetic tests, Amanda K. Sarata, Judith A. Johnson
- Health care quality, enhancing provider accountability through payment incentives and public reporting, Amanda K. Sarata
- Early development and regulation of diagnostic testing for COVID-19, frequently asked questions, Amanda K. Sarata
- Accountable care organizations and the Medicare Shared Savings Program, Amanda K. Sarata
- Employer wellness programs and genetic information, frequently asked questions, Amanda K. Sarata
- Financing and delivery of behavioral health services and the Patient Protection and Affordable Care Act, Amanda K. Sarata, Erin Bagalman
- Mental health parity and the Patient Protection and Affordable Care Act of 2010, Amanda K. Sarata
- COVID-19 variants, vaccines, diagnostics, and therapeutics, Amanda K. Sarata, Agata Bodie, Kavya Sekar
- FDA regulation of laboratory-developed tests (LDTs), Amanda K. Sarata
- Clinical fentanyl testing, Amanda K. Sarata